Please Wait...

IL-6 // Interleukin 6

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Interleukin 6 (IL-6) was initially identified as a differentiation factor for B-cells and was then named: B-cell stimulatory factor 2 (Naka et al., 2002). IL-6 is a pleiotropic cytokine produced by different types of cells (T cells, B cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells and some tumor cells). This cytokine has also a wide range of effect on different target through trans- or classical signaling with the IL-6R system (Calabrese and Rose-John, 2014). This signaling is conditioned by the association of IL-6R (soluble or non-soluble) and IL-6 with two molecules of glycoprotein 130 (gp130). Dysregulation of IL-6 contribute to a wide range of diseases (rheumatoid arthritis, systemic sclerosis, Crohn’s disease, Systemic lupus erythematosus and in tumor progression) (Yao et al., 2014).

Bioclinica Lab employs a high sensitive manual sandwich immunoassay for measurement in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (2 days ago)
RT @isciencebox: Draft and Final FDA Guidances Detail Development of New Drugs for Neurological Disorders @RAPSorg https://t.co/cAewLypUY7
bioclinica (2 days ago)
RT @RAPSorg: Final @US_FDA Rule Requires Medical Device Trials Outside US to Conform to GCP | #Regulatory Focus https://t.co/jgwaqxfiXl #FD…
bioclinica (2 days ago)
Congrats @bioclinica on @Clin_Info_News Best Practices Award 4 "Transformational Med. Imaging in #ClinicalTrials. '… https://t.co/NxauNywq23
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen